Testosterone for schizophrenia

Elias, Alby; Kumar, Ajit

doi:10.1002/14651858.cd006197.pub2

Cited by 15 publications

(11 citation statements)

References 44 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our negative finding on DHEA augmentation is supported by an RCT that could not be included due to insufficient data (Strous et al, 2003), which also reported no significant effects. The results extend a previous review (Elias and Kumar, 2007), in which inconclusive results were found in three trials on DHEA augmentation. We can now state that DHEA augmentation appears to have no beneficial effects on symptom severity in schizophrenia.…”

Section: Discussionsupporting

confidence: 84%

Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review

Heringa

Begemann

Goverde

et al. 2015

Schizophrenia Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 84%

Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review

Heringa

Begemann

Goverde

et al. 2015

Schizophrenia Research

View full text Add to dashboard Cite

“…Many controlled trials of antipsychotics and their combined use with other psychotropic drugs (eg, acetylcholinesterase inhibitors, glutamatergic agents, antidepressants, benzodiazepines, and anticonvulsants) have been carried out in people with treatment-resistant and chronic schizophrenia, particularly on the means for improvement of negative symptoms, quality of life, and social function. However, very limited and weak evidence has been shown to confirm whether a particular antipsychotic medication or any of the combination strategies used could be efficacious in main patient outcomes and/or superior to the others in the treatment of schizophrenia,71–76 and none can be considered a robust treatment or prevention prescription for schizophrenia care 77–84. Nevertheless, psychosocial interventions, together with pharmacological treatment, are recommended to be the most effective strategies in the treatment and rehabilitation of people with schizophrenia 85…”

Section: Patterns In Medication Use: Mono- and Polypharmacymentioning

confidence: 99%

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Chien¹,

Yip²

2013

NDT

View full text Add to dashboard Cite

During the last three decades, an increasing understanding of the etiology, psychopathology, and clinical manifestations of schizophrenia spectrum disorders, in addition to the introduction of second-generation antipsychotics, has optimized the potential for recovery from the illness. Continued development of various models of psychosocial intervention promotes the goal of schizophrenia treatment from one of symptom control and social adaptation to an optimal restoration of functioning and/or recovery. However, it is still questionable whether these new treatment approaches can address the patients’ needs for treatment and services and contribute to better patient outcomes. This article provides an overview of different treatment approaches currently used in schizophrenia spectrum disorders to address complex health problems and a wide range of abnormalities and impairments resulting from the illness. There are different treatment strategies and targets for patients at different stages of the illness, ranging from prophylactic antipsychotics and cognitive–behavioral therapy in the premorbid stage to various psychosocial interventions in addition to antipsychotics for relapse prevention and rehabilitation in the later stages of the illness. The use of antipsychotics alone as the main treatment modality may be limited not only in being unable to tackle the frequently occurring negative symptoms and cognitive impairments but also in producing a wide variety of adverse effects to the body or organ functioning. Because of varied pharmacokinetics and treatment responsiveness across agents, the medication regimen should be determined on an individual basis to ensure an optimal effect in its long-term use. This review also highlights that the recent practice guidelines and standards have recommended that a combination of treatment modalities be adopted to meet the complex health needs of people with schizophrenia spectrum disorders. In view of the heterogeneity of the risk factors and the illness progression of individual patients, the use of multifaceted illness management programs consisting of different combinations of physical, psychological, and social interventions might be efficient and effective in improving recovery.

show abstract

“…There are also consistent findings that males are more vulnerable to schizophrenia’s negative and cognitive symptoms, whereas females are more often afflicted with positive symptoms, show more co-morbid anxiety or depression and tend to respond more quickly and to lower doses of typical and atypical neuroleptic medications (Leung and Chue, 2000, Seeman, 2006, Canuso and Pandina, 2007, Cotton et al, 2009, Ochoa et al, 2012) (Szymanski et al, 1996, Goldstein et al, 2002, Seeman, 2006, Usall et al, 2007, Seeman, 2012). These etiological findings, the significant relationships found between circulating hormone levels and symptom severity in both sexes(Shirayama et al, 2002, Taherianfard and Shariaty, 2004, Ko et al, 2007, Kulkarni et al, 2012, Seeman, 2012) and recent indications of the potential benefits of hormone augmentation as adjuncts to conventional neuroleptic treatment(Elias and Kumar, 2007, Ko et al, 2008, Kulkarni et al, 2012, Torrey and Davis, 2012) give strong impetus to better understand the bases for sex differences in schizophrenia, other psychoses and their treatment. What is lacking is, however, a well-validated animal model in which to conduct this research.…”

Section: Introductionmentioning

confidence: 99%

Acute N-methyl-d-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats

Feinstein

Kritzer

2013

Neuroscience

View full text Add to dashboard Cite

Schizophrenia is a complex constellation of positive, negative and cognitive symptoms. Acute administration of the non-competitive antagonist of the N-methyl D-aspartate receptor (NMDAR) dizocilpine (MK801) in rats is one of few preclinical animal models of this disorder that has both face and/or construct validity for these multiple at-risk behavioral domains and predictive power for the efficacy of therapeutic drugs in treating them. This study asked whether and to what extent the rat NMDAR hypofunction model also embodies the sex differences that distinguish the symptoms of schizophrenia and their treatment. Thus, we compared the effects of acute MK801, with and without pretreatment with haloperidol or clozapine, on seven discrete spontaneous open field activities in adult male and female rats. These analyses revealed that MK801 was more effective in stimulating ataxia and locomotion and inhibiting stationary behavior in females while more potently stimulating stereotypy and thigmotaxis and inhibiting rearing and grooming in males. Haloperidol and clozapine pretreatments had markedly different efficacies in terms of behaviors but strong similarities in their effectiveness in male and female subjects. These results bear intriguing relationships with the complex male/female differences that characterize the symptoms of schizophrenia and suggest possible applications for acute NMDAR hypofunction as a preclinical model for investigating the neurobiology that underlies them.

show abstract

Testosterone for schizophrenia

Abstract: We found one systematic review that met inclusion criteria [1].See PRISMA checklists for assessment of reporting quality.

Cited by 15 publications

References 44 publications

Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review

Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Acute N-methyl-d-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats

Contact Info

Product

Resources

About